SAN DIEGO, CA--(Marketwire - November 12, 2007) - The strength of recent pre-clinical data has given Lpath, Inc. (OTCBB: LPTN) a broader vision for its lead drug candidate, sonepcizumab, in the ophthalmic arena. As recognized category leader in therapeutic agents against bioactive lipids, Lpath now considers sonepcizumab as a potential treatment for a broad range of ocular diseases that extend well beyond “wet” Age-related Macular Degeneration (AMD).
